Amaris Bio

Amaris Bio is a biotechnology company dedicated to developing oral formulations for traditionally injectable biologic drugs. The company's proprietary platform technology is engineered to overcome the physiological barriers of the gastrointestinal tract, allowing for the effective absorption of peptides and proteins. Amaris Bio is currently prioritizing metabolic health, with lead programs focused on oral GLP-1 receptor agonists and oral insulin for the treatment of obesity and diabetes. Their mission is to enhance patient quality of life by replacing frequent injections with convenient oral dosing. The company's approach leverages novel chemistry to enhance the bioavailability of peptides and proteins that are typically poorly absorbed when taken orally.